Ligelizumab continues to trump Xolair in chronic spontaneous urticaria
The Novartis drug can bind to IgE with an 88-fold higher affinity than Xolair.
Read More
Tag: immunoglobulin E
- Kainova reports positive results for DT‑9081 in advanced solid tumours
- EnteroBiotix completes enrolment for trial of EBX‑102‑02
- Lundbeck completes patient randomisation early in global MSA trial
- Incyte treatment for advanced anal cancer approved in Europe
- HUTCHMED begins global trial of novel attc therapy hmpl‑a580 in solid tumours
